New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
11:42 EDTPLUG, ACHN, AMPE, ARWR, VHC, JCP, FOLDOptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD VHC ACHN JCP ARWR PLUG
News For AMPE;FOLD;VHC;ACHN;JCP;ARWR;PLUG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 24, 2014
13:32 EDTJCPJ.C. Penney director discloses 100K share purchase at $7.28
J.C. Penney director Javier Teruel disclosed in a filing late Friday the purchase of 100K shares at $7.28 on Nov. 19. Shares of JCP are up 5.5% in early afternoon trading.
November 21, 2014
10:26 EDTFOLDOptions with decreasing implied volatility
Subscribe for More Information
November 20, 2014
11:49 EDTVHCVirnetX updates licensing declarations to ETSI, ATIS
Subscribe for More Information
06:41 EDTPLUGPlug Power implied volatility of 73 at lower end of index mean range
Subscribe for More Information
November 19, 2014
10:25 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
10:21 EDTFOLDHigh option volume stocks
Subscribe for More Information
07:11 EDTAMPESociety for Free Radical Biology and Medicine to hold annual meeting
Subscribe for More Information
05:44 EDTACHNStocks with implied volatility movement; MCD KO
Subscribe for More Information
November 18, 2014
19:21 EDTFOLDAmicus Therapeutics 13.85M share Secondary priced at $6.50
Subscribe for More Information
10:20 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
09:20 EDTPLUG, FOLDOn The Fly: Pre-market Movers
Subscribe for More Information
09:14 EDTPLUGPlug Power share rise after client installs GenFuel hydrogen infrastructure
Subscribe for More Information
07:32 EDTARWRArrowhead files for regulatory permission to begin Phase I ARC-AAT trial
Arrowhead Research recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate, ARC-AAT, for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Pending approval, Arrowhead intends to proceed with a double blind, placebo-controlled dose escalation, Phase 1 study to determine the safety, tolerability, pharmacokinetics and effect on circulating alpha-1 antitrypsin levels of ARC-AAT in healthy volunteers and patients with alpha-1 antitrypsin deficiency. The study is planned to start in Australia in healthy volunteers and will dose escalate until predetermined levels of alpha-1 antitrypsin reduction are reached. Once these levels of protein knockdown are achieved, the study will transition into a population of patients with ZZ genotype alpha-1 antitrypsin deficiency to further evaluate escalating doses of ARC-AAT. The study is designed to enroll up to 48 subjects, including healthy volunteers and alpha-1 antitrypsin deficiency patients. The application was submitted to an ethics committee in compliance with the Clinical Trial Notification process of the Australian Department of Health and Ageing, Therapeutic Goods Administration.
November 17, 2014
18:32 EDTFOLDOn The Fly: After Hours Movers
Subscribe for More Information
16:24 EDTFOLDOn The Fly: Closing Wrap
Stocks on Wall Street were quiet and traded in a fairly narrow range for their sixth straight session, despite a "merger Monday" that saw over $100B in deals announced. The Dow and S&P, which began the week near record levels, passed back and forth across the flat line several times during the day, though the Nasdaq weakened early in the session and never really recovered. ECONOMIC EVENTS: In the U.S., industrial production fell 0.1% in October, missing expectations for it to have risen 0.2% from the prior month. October capacity utilization came in at 78.9%, which fell short of the expected 79.3% rate. The Empire State manufacturing index, which reflects manufacturing activity in the New York region, rose 4 points to 10.2 in November, which was generally in-line with the consensus forecast. In Asia, Japan's GDP unexpectedly shrank an annualized 1.6% last quarter, missing projections for a 2.2% gain and sinking its economy into a recession. COMPANY NEWS: Actavis (ACT) gained $4.17, or 1.71%, to $247.94 after confirming that it agreed to acquire Allergan (AGN) for a combination of $129.22 in cash and 0.3683 Actavis shares valued at approximately $66B, or $219 per Allergan share. Valeant Pharmaceuticals (VRX), which had been in a contentious fight to buy Allergan, commented that it "cannot justify to its own shareholders" paying a price of $219 or more per share for the Botox maker, whose stock rose $10.55, or 5.31%, to $209.20... Halliburton (HAL), conversely, fell $5.85, or 10.62%, to $49.23 after it agreed to acquire Baker Hughes (BHI) in a stock and cash transaction valued at $78.62 per Baker Hughes share, representing an enterprise value of $38B. When the deal talks were first reported by The Wall Street Journal last week, antitrust concerns were highlighted by analysts, but Halliburton said it had agreed to divest businesses that generate up to $7.5B in revenues, if required by regulators, and agreed to pay a fee of $3.5B if the transaction terminates due to a failure to obtain required approvals. Baker Hughes rose $5.34, or 8.92%, to $65.23 after the deal was announced. MAJOR MOVERS: Among the notable gainers was Celldex Therapeutics (CLDX), which advanced $4.09, or 28.88%, to $18.25 after the company reported it saw a statistically significant overall survival benefit, along with an increase in clinically meaningful tumor shrinkage, in a sub-group of its study of a drug to treat a specific type of brain tumor. Also higher was Amicus Therapeutics (FOLD), which rose $1.01, or 17.75%, to $6.70 after the company announced additional data on secondary endpoints from its second Phase 3 study of its treatment for Fabry disease. Among the noteworthy losers was William Lyon Homes (WLH), which fell $3.52, or 15.53%, to $19.14 after the company announced that it intends to offer, subject to market and other conditions, 1M tangible equity units, which will consist of a prepaid stock purchase contract and an amortizing note. Also lower were shares of DreamWorks (DWA), which dropped $3.71, or 14.26%, to $22.31 after multiple media outlets reported that talks about a takeover of the company by Hasbro (HAS) had ended. INDEXES: The Dow gained 13.01, or 0.07%, to 17,647.75, the Nasdaq lost 17.54, or 0.37%, to 4,671.00, and the S&P 500 added 1.50, or 0.07%, to 2,041.32.
16:01 EDTFOLDAmicus Therapeutics files to sell $75M in common stock
J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering. Cowen and Company, LLC and Leerink Partners are acting as lead managers and Janney Montgomery Scott is acting as co-manager for the offering. The Company expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for migalastat monotherapy for Fabry disease, the continued clinical development of its product candidates and for other general corporate purposes.
14:21 EDTJCPEarnings Preview: Home Depot shares up over 17% since last earnings report
Subscribe for More Information
12:03 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
09:22 EDTFOLDOn The Fly: Pre-market Movers
Subscribe for More Information
November 16, 2014
14:53 EDTFOLDAmicus announces positive data from Fabry monotherapy study
Amicus Therapeutics announced additional positive data on important secondary endpoints from its second Phase 3 study of the oral small molecule chaperone migalastat HCl for Fabry disease. In a poster1 at the American Society of Nephrology Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy, ERT, to migalastat as their only therapy for Fabry disease. Data from the Fabry Registry indicate that the leading cause of death in patients is from cardiac complications2. In Study 012, patients who switched from ERT to migalastat showed a statistically significant decrease from baseline to month 18 in left ventricular mass index-LVMi. LVMi is a measure of cardiac hypertrophy, an increase in the size of the heart that has been associated with an increased risk of cardiac events in Fabry patients."Cardiac disease represents a major cause of morbidity and mortality in Fabry patients that is not adequately addressed with currently available treatment," said Professor Ales Linhart, MD, PhD, a leading expert in the cardiac manifestations of Fabry disease from Charles University of Prague. "The data showing further regression of left ventricular mass in patients switched from ERT to migalastat in this study are very promising since in other cardiac conditions a reduction of cardiac mass typically translates to significant improvements in long term outcomes."
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use